Entia secures £8.8m Series A follow on funding led by BGF to launch its virtual oncology solution.
The investment round was led by BGF with participation from Parkwalk and Sussex Place Ventures.
Entia develops remote patient monitoring technology and predictive analytics to support individuals undergoing cancer treatment. The company combines at-home blood testing with digital solutions to provide personalised health insights.
Medical technology business Entia has secured £8.8m in a Series A follow on funding round led by BGF, with participation from existing seed investors Parkwalk and Sussex Place Ventures. The fresh capital will be deployed to launch the company's virtual oncology solution, Entia Liberty, allowing patients to conduct blood tests from home and helping healthcare teams monitor treatment side effects. The raise follows earlier funding secured by the company earlier in the year, bringing total backing from investors including Innovate UK.
From the founder
"Our approach at Entia is to empower patients with greater freedom whilst also equipping healthcare professionals with the insights to make more informed and personalised clinical decisions."
Toby Basey-Fisher
CEO and Founder at Entia
Investor perspective
"We’re delighted to be making another investment in the UK’s pioneering and thriving healthcare sector, having recently broken the £100 million investment figure in life sciences businesses. Toby and the team have built a fantastic business with technology that is proven and already performing well in the market, providing efficient and accessible solutions for problems facing patients, clinicians, healthcare providers and insurers. Their ambition for future growth is really amazing and we’re excited to be part of the journey."
Zahir Kasmani
Investor, BGF
Use of funds
- 01Continue product development
